13.2 Minnesota Compounding Rules & Beyond-Use Dates

13.2 Minnesota Compounding Rules & Beyond-Use Dates

Quick Answer: Rule 6800.3300 requires Minnesota pharmacies to follow USP <795> (nonsterile) and USP <797> (sterile) and to certify high-alert compound components stage-by-stage. Rule 6800.3350 caps many prepack/unit-of-use beyond-use dates at one year or manufacturer expiration, whichever is less. Minn. Stat. §151.253 draws the line between lawful compounding and manufacturing and sets bulk-substance, “essentially a copy,” and emergency veterinary rules. Hospital sterile operations sit in 6800.7510–7530 with IV labels under 6800.7900. Compounding is prescription-based unless a narrow exception applies.

Section 13.1 built the federal/USP map. This section is the Minnesota statute-and-rule toolkit you must apply on vignettes set in Twin Cities community pharmacies, hospital IV rooms, or veterinary compounding scenarios.

Rule 6800.3300 — Compounding Standards (Minnesota’s USP Hook)

Subpart 1 — Nonsterile. All licensed Minnesota pharmacies that compound nonsterile drug preparations must follow USP chapter 795.

Subpart 2 — Sterile. Any licensed Minnesota pharmacy compounding a sterile product must follow USP chapter 797.

Those two sentences are among the highest-yield Minnesota operations facts in the guide. When a stem asks “what standard applies?” and the product is a cream versus a sterile injectable, answer with the correct chapter because the Board rule says so, not because a textbook suggested it.

Subpart 6 — High-alert certification (effective since January 2, 2013). A pharmacy must develop a list of high-alert compounded preparations for which a pharmacist shall certify that each component used has been accurately weighed, measured, or subdivided at each stage of the compounding procedure to verify conformance with the formula. Subsequent stages may not proceed until that certification occurs.

Exam use: high-alert compounds require pharmacist stage-gate verification of ingredients—technicians may assist under supervision, but the certification checkpoint is a pharmacist control. Connect this to general certification-of-accuracy themes in Rule 6800.3100 and technician rules: the product is not “done” because the balance beeped; it is done when the pharmacist system verifies the process.

Rule 6800.3350 — Beyond-Use Dates (Prepack & Dispensing Containers)

Minnesota’s dedicated BUD rule addresses prepackaging and unit-of-use packaging of already manufactured drugs as much as “compounding science,” but exams group it with dating and labeling discipline.

Critical closing sentence of the rule: nothing in the part supersedes the pharmacist’s professional judgment. That means you may assign a shorter date based on stability, packaging, storage, or USP compounding BUDs—but you do not invent multi-year BUDs that exceed the one-year/manufacturer floor of 6800.3350 for covered packaging.

Do not confuse:

• Manufacturer expiration = dating assigned by the manufacturer for the unopened commercial product under labeled storage.
• Beyond-use date (BUD) = the date after which a repackaged, compounded, or prepared product should not be used.
• USP sterile/nonsterile BUD tables may force much shorter dates for CSPs and compounds than the one-year prepack ceiling.

For compounded sterile preparations, the operative dating framework is USP <797> (via 6800.3300), not a blanket one-year prepack rule. For IV admixtures, Minnesota also requires the beyond-use date on the label under Rule 6800.7900, subp. 5.

Minn. Stat. §151.253 — Compounding vs Manufacturing

Subdivision 1 — Manufacturing license exemption. The manufacturer licensure requirement of §151.252 does not apply to:

1. A practitioner engaged in extemporaneous compounding, anticipatory compounding, or compounding not done pursuant to a prescription drug order when permitted by chapter 151 or Board rules; and
2. A pharmacy in which a pharmacist is engaged in those same activities when permitted by chapter 151 or Board rules.

This is the statutory shield that keeps lawful pharmacy compounding from being treated as unlicensed manufacturing—only when the activity stays inside permitted compounding.

Subdivision 2 — Compounded drug conditions. A drug product may be compounded under §151.253 if a pharmacist or practitioner:

1. Uses bulk drug substances that meet USP/NF monograph (if one exists) and USP pharmacy compounding chapter standards; or, if no monograph, are components of FDA-approved drugs; or appear on the FDA bulk list developed under federal 503A—and are from a registered establishment with valid certificates of analysis;
2. Uses other ingredients that meet applicable USP/NF monographs and USP compounding chapters when monographs exist;
3. Does not compound a drug on the federal list of products withdrawn or removed for safety or lack of effectiveness;
4. Does not compound products that are essentially copies of a commercially available drug product; and
5. Does not compound products identified under federal law as presenting demonstrable difficulties for compounding that reasonably affect safety or effectiveness.

“Essentially a copy” exception: a change made for an identified individual patient that produces a significant difference for that patient, as determined by the prescribing practitioner, between the compounded drug and the commercial product.

Subdivision 3 — Exceptions. Section 151.253 does not apply to compounded PET drugs (§151.01, subd. 38) or radiopharmaceuticals (regulated under their own frameworks).

Subdivision 4 — Emergency veterinary compounding. A pharmacist in a Board-licensed veterinary pharmacy license category may compound and provide a product to a veterinarian without first receiving a patient-specific prescription only when all of the following hold:

1. Needed to treat animals in urgent/emergency situations (health threatened, or suffering/death likely without immediate treatment);
2. Timely access to a compounding pharmacy is not available, as determined by the veterinarian;
3. No suitable FDA-approved commercial drug, or documented shortage;
4. Administered by the veterinarian or bona fide employee, or dispensed to a client in an amount not exceeding what is necessary to treat for ten days;
5. Pharmacy has selected the sterile or nonsterile compounding license category in addition to veterinary pharmacy; and
6. Appropriate DEA registration when the compound contains controlled substances.

Exam framing: emergency vet compounding is a narrow statutory pathway, not a general office-stock free-for-all for human clinics.

Definitions That Drive Minnesota Stems (§151.01)

• Compounding (subd. 35): preparing, mixing, assembling, packaging, and labeling a drug for an identified individual patient pursuant to a prescription drug order; includes anticipatory compounding and nonprescription-component compounds; does not include ordinary reconstitution per FDA-approved labeling; generally must be done pursuant to a prescription drug order unless otherwise permitted.
• Anticipatory compounding (subd. 36): supply sufficient for the pharmacy’s short-term anticipated need for filling prescription drug orders—not wholesale distribution.
• Extemporaneous compounding (subd. 37): compounding pursuant to a prescription issued in advance of the compounding.
• Outsourcing facility (subd. 14b): FDA-registered under 21 U.S.C. §353b (503B).
• Manufacturing (subd. 14): production/processing for resale pathways—excludes prepackaging, extemporaneous, and anticipatory compounding within a licensed pharmacy or by a practitioner when within the definition.

Hospital & Parenteral Rules: 6800.7510–7530 (+ Labeling)

These parts sit in the hospital pharmaceutical service cluster but are prime sterile-compounding operations material.

Rule 6800.7510 — Patient care policies must cover (among other items)

• Preparation, use, and disposal of chemotherapy drugs
• Preparation of compounded sterile products
• Preparation of compounded nonsterile products
• Drug information, adverse reaction reporting, investigational drugs, and related inpatient care controls

Rule 6800.7520 — Pharmaceutical service policies (admixture high yield)

Subp. 1.P requires written precautionary measures, including quality-control documentation, for safe admixture of parenteral products. Admixture preparation is limited to pharmacists, pharmacist-interns, supportive personnel under pharmacist supervision, licensed practitioners, and licensed nurses. Sterile admixtures must be:

• Labeled as required by Rule 6800.7900, and
• Prepared as required by Rule 6800.3300, subp. 2 (USP <797>).

Document retention themes in 6800.7520 include records of packaging, bulk compounding, or manufacturing for two years (or as otherwise required by law)—another inspection-ready compounding trail.

Rule 6800.7530 — Security & emergency access

Only a pharmacist may access the pharmacy except disaster access by the administrator and a tightly cabined emergency nurse withdrawal pathway when the pharmacy is closed (limited doses, documentation left for pharmacist verification). Compounding suites are still pharmacy space—do not invent tech-only after-hours sterile compounding while the pharmacy is closed.

Rule 6800.7900 — Labels that matter for compounds/IVs

Subp. 4: When a drug is added to a parenteral solution, a distinctive supplemental label must be firmly affixed and placed to allow inspection of the infusion and reading of the manufacturer’s solution identity/lot.

Subp. 5 — Intravenous admixtures must be labeled with:

• Name and volume of solution
• Patient’s name
• Bottle sequence or other control number if appropriate
• Name and quantity of each additive
• Infusion/administration rate if appropriate
• Storage requirements if other than room temperature
• Date and time of administration if appropriate
• Beyond-use date
• Ancillary precaution labels

Outpatient compounds still fall under general outpatient labeling (6800.3400 / 6800.4150) plus any compounding-specific identification of ingredients, strength, and dating needed for safe use.

Prescription Basis, Anticipatory Limits & Labeling Discipline

Minnesota’s statutory definition makes the default clear: all compounding must be done pursuant to a prescription drug order unless chapter 151 or Board rules permit otherwise (§151.01, subd. 35). Operational checklist for exam vignettes:

1. Valid order for an identified patient (or lawful anticipatory batch awaiting that order).
2. Formulation legality under §151.253 (bulk quality, not essentially a copy, not withdrawn/difficult-to-compound bans).
3. Environment & process under 6800.3300 / USP <795> or <797> (+ <800> if hazardous).
4. High-alert stage certification when the preparation is on the pharmacy’s high-alert list (6800.3300, subp. 6).
5. Label with identity, strength/ingredients, directions, storage, and BUD as required (IV admixture list above; prepack rules in 6800.3350).
6. Records of compounding/packaging retained (hospital rule floor often two years).
7. Release only after pharmacist (or permitted intern/practitioner) certification pathways are satisfied.

Anticipatory compounding mistakes to avoid on stems:

• Producing months of inventory “just in case” without prescription history/need analysis
• Shipping anticipatory compounds as wholesale stock to other pharmacies
• Calling office-use bulk human compounding “anticipatory” when it is really 503B/manufacturing territory
• Skipping BUD and lot/control documentation because “we’ll label it when it sells”

Putting Minnesota Rules Together

Study Checklist

1. Quote 6800.3300: <795> nonsterile, <797> sterile, high-alert stage certification.
2. Apply 6800.3350: prepack/unit-of-use BUD ≤1 year or mfr EXP, whichever less; professional judgment may shorten.
3. Walk §151.253: manufacturing exemption, bulk rules, no essentially copies, emergency vet 10-day path.
4. List 6800.7900 IV admixture label elements including BUD and each additive.
5. State the default: prescription-based compounding, limited anticipatory short-term need only.

Master these Minnesota hooks and you can answer compounding operations items without needing a full USP reprint in your head.